BTIG lowered the firm’s price target on Staar Surgical (STAA) to $49 from $53 and keeps a Buy rating on the shares. The company’s Q3 results topped estimates, but the bulk of the focus remains on China, which deteriorated through the quarter, and Staar trimmed China’s growth outlook from 10% to 2% for FY24, the analyst tells investors in a research note.